[Comment] Chest wall radiotherapy in SUPREMO: a quality-of-life perspective | ClinicLens

The recently reported SUPREMO trial evaluated chest wall radiotherapy after mastectomy in patients with intermediate-risk breast cancer. Although chest wall radiotherapy did not improve overall survival, local recurrence was reduced (hazard ratio [HR] 0·45 [95%CI 0·20 to 0·99]),

Medical Literature · Updated 2026-08-03

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.